Clinical characteristics of subjects with symptoms of α 1- antitrypsin deficiency older than 60 years

Michael A Campos, Saleh Alazemi, Guoyan Zhang, Matthias A Salathe, Adam Wanner, Robert A. Sandhaus, Horst Baier

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The clinical characteristics of elderly subjects with α 1-antitrypsin deficiency (AATD)-associated COPD have not been described. Methods: The clinical, demographic, health-related quality of life (HRQoL) characteristics and 1-year exacerbation rates of 275 subjects with AATD and COPD receiving augmentation therapy aged > 59 years (mean [± SD] age, 66.3 ± 5.7 years) were compared to those of 354 subjects aged 50 to 59 years (mean age, 54.3 ± 2.8 years) and 293 subjects < 50 years (mean age, 43.9 ± 3.8 years). Results: Older subjects received diagnoses later in life (mean age at diagnosis, 55.0 ± 8.5 years) and had a longer diagnostic delay (mean age at diagnosis, 12.9 ± 14.3 years) than subjects in the other two age groups. Although the proportion of lifetime nonsmokers was higher in the older group, the majority (64%) had significant tobacco exposure but with a longer interval of tobacco abstinence. The mean FEV 1 values (n = 641) were similar between the three age groups, suggesting a slower disease progression in the oldest group. Subjects in the older group were less symptomatic, had less concomitant asthma, and had significantly better scores in most domains of two HRQoL instruments. During follow-up, older subjects had fewer acute exacerbations. Conclusions: Subjects with AATD-associated COPD who reach an older age exhibit a more indolent clinical course than younger affected individuals, possibly related in part to differences in tobacco exposure. This finding supports current guidelines that recommend screening of all patients with COPD for AATD, regardless of their age and prior smoking history.

Original languageEnglish
Pages (from-to)600-608
Number of pages9
JournalChest
Volume135
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

Chronic Obstructive Pulmonary Disease
Tobacco
Age Groups
Quality of Life
Delayed Diagnosis
Disease Progression
Asthma
Smoking
History
Demography
Guidelines
Therapeutics

Keywords

  • α -antitrypsin deficiency
  • Age groups
  • COPD
  • Quality of life

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Clinical characteristics of subjects with symptoms of α 1- antitrypsin deficiency older than 60 years. / Campos, Michael A; Alazemi, Saleh; Zhang, Guoyan; Salathe, Matthias A; Wanner, Adam; Sandhaus, Robert A.; Baier, Horst.

In: Chest, Vol. 135, No. 3, 01.03.2009, p. 600-608.

Research output: Contribution to journalArticle

Campos, Michael A ; Alazemi, Saleh ; Zhang, Guoyan ; Salathe, Matthias A ; Wanner, Adam ; Sandhaus, Robert A. ; Baier, Horst. / Clinical characteristics of subjects with symptoms of α 1- antitrypsin deficiency older than 60 years. In: Chest. 2009 ; Vol. 135, No. 3. pp. 600-608.
@article{1d6b346cb7194ed2a6914e9948a9a12d,
title = "Clinical characteristics of subjects with symptoms of α 1- antitrypsin deficiency older than 60 years",
abstract = "Background: The clinical characteristics of elderly subjects with α 1-antitrypsin deficiency (AATD)-associated COPD have not been described. Methods: The clinical, demographic, health-related quality of life (HRQoL) characteristics and 1-year exacerbation rates of 275 subjects with AATD and COPD receiving augmentation therapy aged > 59 years (mean [± SD] age, 66.3 ± 5.7 years) were compared to those of 354 subjects aged 50 to 59 years (mean age, 54.3 ± 2.8 years) and 293 subjects < 50 years (mean age, 43.9 ± 3.8 years). Results: Older subjects received diagnoses later in life (mean age at diagnosis, 55.0 ± 8.5 years) and had a longer diagnostic delay (mean age at diagnosis, 12.9 ± 14.3 years) than subjects in the other two age groups. Although the proportion of lifetime nonsmokers was higher in the older group, the majority (64{\%}) had significant tobacco exposure but with a longer interval of tobacco abstinence. The mean FEV 1 values (n = 641) were similar between the three age groups, suggesting a slower disease progression in the oldest group. Subjects in the older group were less symptomatic, had less concomitant asthma, and had significantly better scores in most domains of two HRQoL instruments. During follow-up, older subjects had fewer acute exacerbations. Conclusions: Subjects with AATD-associated COPD who reach an older age exhibit a more indolent clinical course than younger affected individuals, possibly related in part to differences in tobacco exposure. This finding supports current guidelines that recommend screening of all patients with COPD for AATD, regardless of their age and prior smoking history.",
keywords = "α -antitrypsin deficiency, Age groups, COPD, Quality of life",
author = "Campos, {Michael A} and Saleh Alazemi and Guoyan Zhang and Salathe, {Matthias A} and Adam Wanner and Sandhaus, {Robert A.} and Horst Baier",
year = "2009",
month = "3",
day = "1",
doi = "10.1378/chest.08-1129",
language = "English",
volume = "135",
pages = "600--608",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Clinical characteristics of subjects with symptoms of α 1- antitrypsin deficiency older than 60 years

AU - Campos, Michael A

AU - Alazemi, Saleh

AU - Zhang, Guoyan

AU - Salathe, Matthias A

AU - Wanner, Adam

AU - Sandhaus, Robert A.

AU - Baier, Horst

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background: The clinical characteristics of elderly subjects with α 1-antitrypsin deficiency (AATD)-associated COPD have not been described. Methods: The clinical, demographic, health-related quality of life (HRQoL) characteristics and 1-year exacerbation rates of 275 subjects with AATD and COPD receiving augmentation therapy aged > 59 years (mean [± SD] age, 66.3 ± 5.7 years) were compared to those of 354 subjects aged 50 to 59 years (mean age, 54.3 ± 2.8 years) and 293 subjects < 50 years (mean age, 43.9 ± 3.8 years). Results: Older subjects received diagnoses later in life (mean age at diagnosis, 55.0 ± 8.5 years) and had a longer diagnostic delay (mean age at diagnosis, 12.9 ± 14.3 years) than subjects in the other two age groups. Although the proportion of lifetime nonsmokers was higher in the older group, the majority (64%) had significant tobacco exposure but with a longer interval of tobacco abstinence. The mean FEV 1 values (n = 641) were similar between the three age groups, suggesting a slower disease progression in the oldest group. Subjects in the older group were less symptomatic, had less concomitant asthma, and had significantly better scores in most domains of two HRQoL instruments. During follow-up, older subjects had fewer acute exacerbations. Conclusions: Subjects with AATD-associated COPD who reach an older age exhibit a more indolent clinical course than younger affected individuals, possibly related in part to differences in tobacco exposure. This finding supports current guidelines that recommend screening of all patients with COPD for AATD, regardless of their age and prior smoking history.

AB - Background: The clinical characteristics of elderly subjects with α 1-antitrypsin deficiency (AATD)-associated COPD have not been described. Methods: The clinical, demographic, health-related quality of life (HRQoL) characteristics and 1-year exacerbation rates of 275 subjects with AATD and COPD receiving augmentation therapy aged > 59 years (mean [± SD] age, 66.3 ± 5.7 years) were compared to those of 354 subjects aged 50 to 59 years (mean age, 54.3 ± 2.8 years) and 293 subjects < 50 years (mean age, 43.9 ± 3.8 years). Results: Older subjects received diagnoses later in life (mean age at diagnosis, 55.0 ± 8.5 years) and had a longer diagnostic delay (mean age at diagnosis, 12.9 ± 14.3 years) than subjects in the other two age groups. Although the proportion of lifetime nonsmokers was higher in the older group, the majority (64%) had significant tobacco exposure but with a longer interval of tobacco abstinence. The mean FEV 1 values (n = 641) were similar between the three age groups, suggesting a slower disease progression in the oldest group. Subjects in the older group were less symptomatic, had less concomitant asthma, and had significantly better scores in most domains of two HRQoL instruments. During follow-up, older subjects had fewer acute exacerbations. Conclusions: Subjects with AATD-associated COPD who reach an older age exhibit a more indolent clinical course than younger affected individuals, possibly related in part to differences in tobacco exposure. This finding supports current guidelines that recommend screening of all patients with COPD for AATD, regardless of their age and prior smoking history.

KW - α -antitrypsin deficiency

KW - Age groups

KW - COPD

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=62149113261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62149113261&partnerID=8YFLogxK

U2 - 10.1378/chest.08-1129

DO - 10.1378/chest.08-1129

M3 - Article

VL - 135

SP - 600

EP - 608

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -